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Abstract
Cycloserine (CS, 4-amino-3-isoxazolidone) is a cyclic amino acid mimic that is known to inhibit
many essential pyridoxal 5′-phosphate (PLP)-dependent enzymes. Two CS enantiomers are
known; D-cycloserine (DCS, also known as Seromycin), is a natural product that is used to treat
resistant Mycobacterium tuberculosis infections as well as neurological disorders since it is a
potent NMDA receptor agonist, and L-cycloserine (LCS), is a synthetic enantiomer whose
usefulness as a drug has been hampered by its inherent toxicity arising through inhibition of
sphingolipid metabolism. Previous studies on various PLP-dependent enzymes revealed a
common mechanism of inhibition by both enantiomers of CS; the PLP cofactor is disabled by
forming a stable 3-hydroxyisoxazole/pyridoxamine 5′-phosphate (PMP) adduct at the active site
where the cycloserine ring remains intact. Here we describe a novel mechanism of CS inactivation
of the PLP-dependent enzyme serine palmitoyltransferase (SPT) from Sphingomonas
paucimobilis. SPT catalyses the condensation of L-serine and palmitoyl-CoA, the first step in the
de novo sphingolipid biosynthetic pathway. We have used a range of kinetic, spectroscopic and
structural techniques to postulate that both LCS and DCS inactivate SPT by transamination to
form a free pyridoxamine 5′-phosphate (PMP) and β-aminooxyacetaldehyde that remain bound at
the active site. We suggest this occurs by ring opening of the cycloserine ring followed by
decarboxylation. Enzyme kinetics show that inhibition is reversed by incubation with excess PLP
and that LCS is a more effective SPT inhibitor than DCS. UV-visible spectroscopic data,
combined with site-directed mutagenesis, suggest that a mobile Arg378 residue is involved in
cycloserine inactivation of SPT.
Introduction
Sphingolipids are a large family of bioactive molecules that are found in all eukaryotic and
some prokaryotic membranes. An important example is sphingomyelin, a constituent of the
protective myelin sheath that surrounds nerve cells (1). Sphingolipids can associate with
cholesterol to form ‘lipid rafts’ or sphingolipid-based microdomains necessary for signal
transduction and membrane trafficking (2). Sphingolipid metabolites such as ceramides and
*corresponding author.
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are awaiting acceptance.
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sphingosine-1-phosphate play important roles in cell proliferation, differentiation and
apoptosis (3-5) and it follows that pharmaceutical intervention that regulates the
sphingolipid metabolic pathway could help to combat pathological processes such as
carcinogenesis (6), atherosclerosis (7) and Parkinson’s disease (8).
The de novo biosynthetic pathway for sphingolipids varies from one organism to another but
the first and rate-limiting step is common to all: condensation of L-serine with palmitoyl-
CoA to form 3-ketodihydrosphingosine (9). This step is catalysed by the pyridoxal 5′-
phosphate (PLP)-dependent enzyme serine palmitoyltransferase (SPT), a member of the α-
oxoamine synthase (AOS) subfamily. Other members of this subfamily that have been well
characterised include 8-amino-7-oxononanoate synthase (AONS) (10,11), 5-aminolevulinate
synthase (ALAS) (12,13) and 2-amino-3-ketobutyrate-CoA ligase (KBL) (14). These
enzymes catalyse reactions in heme biosynthesis, biotin biosynthesis and threonine
degradation, respectively. Recent additions to the growing list of identified AOS enzymes
are the bacterial quorum-sensing autoinducer synthases CqsA in Vibrio cholerae (15-17) and
LqsA in Legionella pneumophila (17).
The AOS enzymes utilise a PLP cofactor at the active site to catalyse the Claisen-like
condensation between an amino acid and an acyl-CoA substrate. The first high resolution
crystal structure of the holo-form of a bacterial, homodimeric SPT from Sphingomonas
paucimobilis clearly shows the cofactor covalently attached to the side-chain of a conserved
Lys265 residue via a Schiff’s base (also known as an internal aldimine) at the dimer interface
(18). Transaldimination occurs when the L-serine substrate binds at the active site to form an
external aldimine that is stabilised by other conserved residues; a His159 that stacks above
the PLP ring and His234 that hydrogen bonds with the PLP-bound intermediate (19). The
crystal structure of the enzyme-bound PLP:L-serine external aldimine complex has recently
been resolved for SPTs from the sphingolipid-producing bacteria S. paucimobilis (20) and
Sphingobacterium multivorum (21). The proposed steps subsequent to formation of the
external aldimine are: deprotonation at Cα of the external aldimine complex to form a
quinonoid (carbanion equivalent) intermediate; a Claisen condensation with the acyl-CoA
substrate and loss of free CoASH to form a β-ketoacid intermediate; decarboxylation to
form a product quinonoid; protonation of this quinonoid to form the product external
aldimine; release of the α-oxoamine product and regeneration of the enzyme PLP internal
aldimine (Fig. 1).
Both enantiomers of cycloserine (Fig. 2A) can be thought of as cyclic analogues of serine
and/or alanine and have been shown to be irreversible inhibitors of many PLP-dependent
transaminases (22), racemases (23) and decarboxylases (24). L-cycloserine (LCS) is prepared
synthetically whereas D-cycloserine (DCS) is a natural product isolated from Streptomyces
strains (25) and is a broad spectrum antibiotic. Due to its severe side effects DCS is most
commonly used as a second-line drug in combination therapy to treat tuberculosis (26). DCS
is also used in neurological studies since it is a potent agonist of N-methyl-D-aspartic acid
(NMDA) receptors that are involved in neurotransmission (27). One of its main antibacterial
targets is the PLP-dependent alanine racemase (28,29), an essential enzyme that generates D-
alanine for the formation of the D-alanyl-D-alanine dipeptide incorporated into the bacterial
peptidoglycan layer. Unlike many irreversible inhibitors that inactivate their protein targets
by covalent modification, CS renders its targets inactive by forming a stable adduct with the
essential PLP cofactor. It is not surprising that CS has also been shown to be a potent
inhibitor of bacterial SPT (30) as well as mammalian SPT in mouse brain microsomes (31).
Although LCS is commonly used as a regulator of lipid metabolism in biological research,
its mechanism of inhibition is still unknown. In this paper we used a combination of x-ray
crystallography, mass spectrometry, UV-Vis spectroscopy and enzyme kinetics to elucidate
the mechanism of SPT inactivation by both enantiomers of CS. We highlight differences in
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the enantiospecific inhibition observed for both LCS and DCS and provide further insight
into PLP-dependent chemistry.
Results
Both LCS and DCS are irreversible inhibitors of serine palmitoyltransferase
When either LCS or DCS was incubated with SPT, enzyme activity decreased over time.
Log plots of % activity remaining versus time, according to the method of Kitz and Wilson
(32), were linear for each enantiomer indicating classical time-dependent inactivation of
SPT activity (Fig. 3A and 3B). We noted that the Kitz and Wilson secondary plots (Fig. 3C)
appeared to pass very close to the origin - there are many examples of this in the literature
such as the inhibition of the thiamine-dependent enzyme benzaldehyde lyase (BAL) by
methyl benzoylphosphonate (33) and the inhibition of the PLP-dependent γ-aminobutyric
acid aminotransferase (GABA-AT) by (1S,3S)-3-amino-4-difluoromethylene-
cyclopentanecarboxylic acid (34). Kitz and Wilson replots of this nature suggest that both
DCS and LCS form very weak complexes with SPT but inactivation is fast compared with
the formation of the CS:SPT complexes. Moreover, these prevent the estimation of the kinact
and KI values directly. In comparison with LCS, we found that approximately 15-fold higher
concentrations of DCS were required to inactivate SPT activity to the same extent and over a
similar period of time. From the secondary plot of 1/kapp versus 1/[cycloserine] the second-
order rate constant of inactivation kinact/KI was calculated as 1/slope for each inhibitor (Fig.
3C). LCS (kinact/KI = 0.83 ± 0.5 M−1 s−1) was found to be ~14-fold more effective at
inactivating SPT than DCS (kinact/KI = 0.06 ± 0.002 M−1 s−1).
Activity of SPT, measured by monitoring formation of the free thiol of CoASH using a
continuous DTNB assay (20) was reduced to 1 % and 22 % after 2 hours inhibition with 5
mM LCS and DCS, respectively (Fig. 4). When these samples were dialysed against buffer
in the absence of free PLP we noted that enzyme activity was not recovered. In contrast,
activity returned to 83 % (LCS) and 79 % (DCS) of the original activity after dialysis
against buffer containing 25 μM PLP. The fact that activity can be recovered upon dialysis
against PLP shows that inactivation by both enantiomers does not occur through covalent
modification of the protein but rather by disabling the PLP cofactor.
UV-visible spectroscopy analysis of LCS and DCS binding to holo- SPT
The UV-visible spectrum of holo-SPT displays absorbance maxima at 336 nm and 425 nm
corresponding to the enolimine and ketoenamine forms of the PLP-bound enzyme,
respectively (Fig. 5A and 5B, solid line). When LCS (5 mM) was added to the enzyme at pH
7.5 and 25°C, notable changes in these peaks occurred suggesting that LCS interacts with
the PLP cofactor (Fig. 5A, dashed lines). Over a period of ~30 minutes the ketoenamine
peak (425 nm) was reduced to ~10 % of its original value with concomitant growth of new
peaks at 330 nm and 380 nm. No further changes in this UV-vis spectrum were observed
when the sample was incubated for ~8hrs. This suggests that the PLP cofactor bound to
residue Lys265 as an internal aldimine is displaced and one or more new species are formed.
A number of mechanisms have been proposed for cycloserine inhibition of a range of PLP-
dependent enzymes and have been collated by Olson et al. (35). In one mechanism
originally proposed for the inhibition of alanine racemase, the authors speculate that the
cycloserine ring of the inhibitor-PLP adduct is opened after attack by either an active site
nucleophile on the enzyme or hydroxide ion (36,37). In the case of S. paucimobilis SPT
Ikushiro et al. (30) proposed that hydrolysis of the ring-open adduct leads to formation of
free pyridoxamine 5′-phosphate (PMP) and beta-aminooxypyruvate (Fig. 2C). They
speculated that the 380 nm peak that they observed upon incubation of SPT with LCS could
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be due to formation of a transient oxime intermediate while the 330 nm peak is due to the
ring-opened adduct prior to hydrolysis (Fig. 2C). Of interest, a similar UV-vis spectrum was
obtained in a study of the interaction of LCS with ArnB, the PLP-dependent
aminotransferase involved in amino arabinose biosynthesis (38). X-ray structure analysis of
that inactivated enzyme revealed a bound hydroxyisoxazole-PLP adduct at the ArnB active
site. Therefore it appears that LCS can interact with its target enzymes in different ways
with the cycloserine ring remaining intact or undergoing ring cleavage.
Dramatic changes in the PLP absorbance spectrum of holo-SPT were also observed within
30 seconds after addition of DCS (Fig. 5B, dashed line) but changes thereafter were much
slower compared to LCS, occurring over a period of ~10 hours (Fig. 5B, dotted and dot-dash
lines). These spectroscopic changes correlate with the observation that DCS inactivates SPT
activity at a slower rate than LCS (see Fig. 3). Loss of the 425 nm peak was accompanied by
appearance of a new peak at 380 nm. Over time (~2-10 hrs) this peak shifted to 365 nm
along with the slow appearance of a pronounced, broad shoulder with λmax at 330 nm. In
contrast to the changes that occurred in the presence of LCS the 380 nm peak was the most
dominant and not the 330 nm peak. Since DCS is a much slower inhibitor than LCS a build-
up of intermediates along with slower formation of products might be expected and tends to
agree with Ikushiro’s proposition (30) that the LCS-derived 380 nm peak could be that of an
oxime intermediate, while the slow build-up of products is represented by the slowly-formed
330 nm shoulder.
The UV-vis spectra of holo-SPT in the presence of LCS and DCS (Fig. 5A and 5B) are very
different to each other. In contrast, the spectra of free PLP in the presence of both CS
enantiomers are identical and display maxima at 360 nm (Supplementary Fig. 1A and 1B).
Therefore it is clear that the enzyme does not simply accommodate a PLP-cycloserine
aldimine that is formed between the cofactor and inhibitor in solution. The new 330 nm peak
observed in the spectrum of the enzyme in the presence of both CS enantiomers is similar to
the λmax (320 nm) for free PMP (Supplementary Fig. 1C) and could be due to bound PMP.
Identification of SPT-cycloserine reaction products by LC-MS
The reaction products after inactivation of SPT by both CS enantiomers were analysed by
LC ESI-MS (Supplementary Fig. 2). After 30 mins inactivation, low molecular weight
products were separated from the protein by centrifugation through a filter with a 3 kDa cut-
off. Analysis of this sample by LC ESI-MS showed a peak in the single ion monitoring
(SIM) at m/z = 248 with a total ion count (TIC) above background at 2.8 min that
corresponds to PMP (Supplementary Fig. 2B). We were unable to detect an ion above
background corresponding to the aminooxyaldehyde so the filtrate was derivatised with 2,4-
dinitrophenylhydrazine (2,4-DNP) to form the corresponding hydrazone (chemical formula
C8H9N5O5 = 255.06, Supplementary Fig. 2A). When the 2,4-DNP derivatised sample was
analysed by LC-MS a clear peak eluted from the C18 column at 3.1 minutes that ionized
very well above background (Supplementary Fig. 2C). Electrospray MS analysis of this
peak revealed it to have m/z = 256 (Supplementary Fig. 2C) which corresponds to the [M
+H]+ ion of the 2,4-DNP derivative of β-aminooxyacetaldehyde derived from LCS. No
peaks were observed for free PLP and a 2,4-DNP derivative of the PLP aldehyde. These
peaks were not observed for control SPT samples treated in the same way but in the absence
of cycloserine (data not shown). We carried out a similar analysis of SPT after incubation
with DCS. We observed the same peaks as seen in the LCS analysis but the total ion counts
were much lower overall and the UV trace was more complicated, unsurprising given the
slower rate of reaction with this enantiomer (data not shown). We conclude that LCS
inactivation of SPT results in the formation of PMP and β-aminooxyacetaldehyde from the
cycloserine ring.
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Structure of S. paucimobilis SPT after inactivation by L-cycloserine
Crystals of SPT:LCS-derived complex were prepared by co-crystallisation in the presence of
1 mM LCS. Colourless crystals were obtained that diffracted to a resolution of 1.4 Å. We
used our previous 1.3 Å resolution structure of the holo-form of S. paucimobilis SPT with
the PLP and water molecules to solve the structure of this new complex (18). It was clear
that in the SPT:LCS complex the PLP cofactor is no longer covalently attached to the
sidechain of Lys265 (contoured at 3σ and 0.2 Å−3) and that the lysine side-chain adopts a
conformation similar to that observed in the SPT:L-ser external aldimine complex (20) (Fig.
6A). The experimental electron density cannot definitively assign the co-factor as either PLP
(an aldehyde) or PMP (amine), as the density is very weak for the terminal atom. However,
in light of the mass spectrometry results we have modeled the co-factor as PMP. There is no
additional density that could be modeled by either free cycloserine or an isoxazole ring,
which have been observed in other cycloserine-inactivated PLP dependent enzymes (Table
1). Nor could such additional groups fit into the structure given the position of the side
chains and a clearly identified water molecule (Fig. 6B). We do note that unusually the side
chain of Tyr73 is disordered in the structure. The aromatic ring of the pyridoxal co-factor
essentially rotates ~23 ° about an axis which links the C2 and C5 atoms. The phosphate
group has not moved and the interactions with the protein are largely conserved, although
there are some changes in water structure. In this new structure the side chains of Arg378 and
Gln357 which were noted to make a salt interaction in the holo form (18) are disordered
confirming this is a flexible region of the protein. In contrast, in the PLP:L-ser complex the
loop containing Arg378 moves into the active site to allow the Arg378 side-chain to make a
salt contact with L-ser carboxylate (Fig. 6B). Interestingly there is an additional ‘blob’ of
difference electron density lying adjacent to the PMP cofactor and parallel to Lys265. This
blob sits at the interface of the two subunits of the functional SPT dimer. If the density is
contoured at 0.16 e Å−3 (2.7σ ) it has a continuous nature (Fig. 6B). We have not fitted this
density in the final model but in light of the mass spectrometry data have rendered it as the
β-aminooxyacetaldehyde. We have been unable to grow x-ray diffraction quality crystals of
DCS-inactivated SPT and this is the focus of current research.
Inactivation of a SPT R378N mutant by LCS and DCS
We recently determined the crystal structure of the SPT:L-serine external aldimine complex
that allowed us to identify any changes that occur during formation of this key intermediate
from the internal aldimine holo-SPT form. The major difference between the two forms was
the movement of Arg378 from a “swung-out” position (bound to the side-chain of Gln357) to
a “swung in” position allowing it to form a salt bridge with the −CO2− group of the L-ser
substrate (20) (Fig. 6B). This Arg378 residue appears to be highly mobile in S. paucimobilis
SPT and we had probed its role in catalysis and found that a SPT R378N mutant was still
active albeit at ~40x fold reduced rate when compared with the wild-type enzyme. We
inhibited the SPT R378N mutant with LCS and DCS to investigate the mechanism of
cycloserine inhibition. The UV-visible spectrum of the SPT R378N holo-enzyme is similar
to that of the wild-type SPT showing absorbance maxima at 336 nm and 415 nm
corresponding to the enolimine and ketoenamine tautomers of the PLP-bound enzyme,
respectively (Fig. 7A and 7B, solid line). When LCS (5 mM) was added to the mutant
enzyme, a decrease in the 415 nm peak was observed over 30 mins along with the
appearance of a new peak at 330 nm and a small shoulder at 380 nm (Fig. 7A). Upon
completion of the LCS inactivation of the SPT R378N mutant we noted that the 380 nm
peak (Fig. 7A) is notably smaller than that observed in the wild-type enzyme (Fig. 5A,
dashed line) suggesting that in the absence of Arg378 the mutant enzyme is unable to
stabilize the putative oxime intermediate.
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In contrast to the LCS enantiomer, when DCS was added to the SPT R378N mutant,
dramatic changes in the UV-visible spectrum occurred within the mixing time (Fig. 7B,
dashed line). Most noticeable was the appearance of new a peak at 495 nm which was
transient and disappeared after 30 seconds. This could be due the formation of a quinonoid
species – these have been observed with SPT and other members of the AOS family only
when incubated with substrates and substrate analogues and products, and have
characteristic absorbance maxima >480 nm (11,15,16,39,40). In the case of SPT, Ikushiro et
al. (39) used a palmitoyl-CoA thioether analogue to initiate deprotonation of the PLP:L-ser
external aldimine and the resulting quinonoid was observed as a new peak in the UV-visible
spectrum with λmax = 493 nm. In addition to the 495 nm peak, DCS binding to SPT R378N
induced formation of a broad peak with a plateau from 340 nm to 380 nm along with a small
shoulder at 425 nm (Fig. 7B). We suggest that the broad peak is likely to be a combination
of overlapping bands due to a number of PLP-derived species. The peak shifted only slightly
over the following 30 minutes and was an indication that maybe a DCS-derived intermediate
becomes ‘stalled’ in the SPT R378N mutant. LC ESI-MS analyses of the low molecular
weight fraction from both the CS enantiomer-inactivated R378N incubations were
inconclusive e.g. no ions corresponding to the PMP and β-aminooxyacetaldehyde products
could be detected (data not shown). This is unsurprising since the R378N mutant has such a
slow turnover compared with the wild-type enzyme. Taken together, the analyses of the SPT
R378N mutant with both LCS and DCS provide further evidence that the SPT enzyme is
controlling the reaction pathway of each inhibitor in a stereospecific manner that requires
residues not simply involved in binding the PLP cofactor directly. Current efforts are
focused on capturing CS-derived intermediates in the mutant enzyme by x-ray
crystallography.
Discussion
The antibiotic DCS was first isolated from the soil bacterium Streptomyces and its structure
and activity determined over 50 years ago (41-45). Cycloserine inactivates many PLP-
dependent enzymes by disabling the essential PLP cofactor at the active site and a list of the
x-ray structures from the Protein DataBank with cycloserine adducts bound in the active site
is presented in Table 1. In each case inhibitor binding results in transaldimination of the PLP
bound, holo-enzyme and leads to formation of a PLP:cycloserine external aldimine.
Deprotonation of this species gives rise to a stable 3-hydroxyisoxazole-PMP adduct whereby
the cycloserine ring remains intact and covalently linked to the PLP cofactor – the so-called
“aromatisation mechanism” (35) (Fig. 2B). Olson et al. studied LCS inactivation of γ-
aminobutyric acid aminotransferase and Peisach et al., investigated D-amino acid
aminotransferase inhibition by DCS (46). The aromatized CS adduct was observed in both
cases where the active site lysine residue was inferred as the base which removes the CS α-
proton. It is interesting that inhibition by both enantiomers of CS leads to formation of the
same isoxazole-PMP adduct in the alanine racemase that was studied by Fenn et al. (23).
This could be due to the alternating acid/base nature of the residues (Lys39, that is also
involved in formation of the initial internal aldimine with PLP, and the side-chain of Tyr265)
from an enzyme that catalyses racemisation of both enantiomers of alanine. However, this
study revealed that the kinetics of inactivation of the two CS enantiomers was different;
DCS inactivated alanine racemase much faster than the LCS. This explains why DCS
(seromycin) is the better antibiotic. We also found different kinetics for each CS enantiomer
with SPT; the apparent half-life of inactivation was approximately 15 minutes for 1.25mM
LCS and 20mM DCS. Kitz and Wilson analysis also revealed both enantiomers inhibit via a
bimolecular mechanism i.e. they are weak, but fast inhibitors, and suggests that carrying out
incubations at lower temperatures would provide further insight into the inhibition
mechanism (32).
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Since SPT only catalyses condensation between palmitoyl-CoA and L-serine (although it
does bind D-serine and forms an external aldimine) we expected to observe differences in
SPT inactivation by each CS enantiomer. These were manifested in differences in both the
rates of inactivation, with LCS being 14 times faster than DCS, and time-dependent changes
in the UV-vis spectra. We could not detect an aromatised CS derivative after inactivation,
but we did identify PMP and the derivitised form of a novel aldehyde by mass spectrometry.
This CS-derived product was formed from both enantiomers but to a greater extent (based
on LC ESI-MS profiles) from LCS inactivation. Moreover, we also identified a PMP form
of the cofactor in crystals of the LCS-inactivated SPT and a low molecular weight species
non-covalently bound at the active site which clearly no longer contains a cycloserine ring
and whose size and shape is consistent with the proposed β-aminoacetaldehyde product.
This combined data leads us to propose a novel decarboxylative, ring-opening mechanism
for inactivation of SPT by cycloserine (Fig. 8). The first step in the normal catalytic cycle of
SPT is a transaldimination step when the substrate L-Ser replaces the PLP-Lys265 internal
aldimine to form a PLP:L-ser external aldimine (Fig. 1). Deprotonation of this species does
not occur until the second substrate palmitoyl-CoA binds. It is interesting to note that SPT
acts upon both CS enantiomers in the absence of palmitoyl-CoA suggesting that the CS
binds in the SPT active site and forms a PLP:CS external aldimine complex which then
reacts readily. Previously, we captured the PLP:L-ser external aldmine and the structure
revealed the Lys265 poised below this intermediate at a position where it would act as the
base that removes the Cα proton (to form a quinonoid) once binding of the thioester causes
rotation around the Cα-N bond (20). Interestingly, D-ser can form an external aldimine with
SPT but is a poor substrate presumably because the α-H is not in the correct position when
palmitoyl-CoA binds (47). To rationalise why we did not observe aromatization of the LCS
inhibitor (which has the same S-configuration as L-ser) we suggest that the Cα proton in the
PLP:LCS external aldimine cannot be in the optimal orientation to be removed by the lysine
(Fig. 1 and Fig. 8A). Instead we propose ring-opening of the LCS ring by cleavage of the
amide bond. Amide bond hydrolysis of peptides is catalysed by various proteases which use
a powerful nucleophile (e.g. serine or cysteine in the serine or cysteine proteases) to attack
this bond and generate an acylated intermediate which is subsequently hydrolysed. We
cannot identify such a residue in the active site of SPT at present but conformational
changes upon ligand binding may bring such a residue into play. An acylated ring-opened
adduct was recently captured by Macheboeuf et al who studied the inhibition of penicillin-
binding protein (PBP) by the natural product lactivicin (LTV) (48). This interesting
molecule contains separate cycloserine and γ-lactone rings and is the only known natural
PBP inhibitor that does not contain a β-lactam. Crystallographic analysis of the PBP
revealed that LTV inhibition involves opening of both the cycloserine and γ-lactone rings
upon attack by the active site serine nucleophile. We have accommodated this possible route
(Fig. 8, path (a)) into the mechanism and the acylated intermediate formed could be
hydrolysed to give the carboxylated PLP intermediate.
We also suggest an alternative mechanism involving direct attack of water on the CS ring
(Fig. 8, path (b)). This is justified when one considers the properties of cycloserine. During
the initial characterization of the DCS natural product Kuehl et al and Hidy et al found the
CS ring opened upon treatment with methanol and HCl to afford the β-amino-D-alanine
methyl ester (43,44). Treatment of this ester with alkali converted it back to DCS. Further
studies revealed unusual chemical properties of DCS; it was found to dimerise to give a six-
membered cis-3-6-bis(aminooxymethyl)-2,5-piperazinedione adduct in acid (44,49). The
proposed mechanism of adduct formation involves nucleophilic attack of one CS amino
group at the carbonyl position of another CS molecule, which then ring opens at the amide
bond to generate the aminooxy form. This reaction occurs again in an intramolecular fashion
to generate the piperazine ring. So, in the context of a SPT catalysed mechanism ring-
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opening could also proceed through acid catalysis and a number of potential proton donors
are found in the active site (e.g. His159).
We predict two possible routes for the ring-opened adduct. Firstly, it can form an oxime
intermediate, observed as a 380 nm peak in the UV-visible spectrum (Fig. 2C and Fig. 5A).
In the second, novel route, the ring-open adduct decarboxylates, which is then followed by
imine hydrolysis to form the products, PMP and β-aminooxyacetaldehyde (Fig. 8). This fits
well with the SPT mechanism since the enzyme catalyses decarboxylation of the putative β-
keto acid Claisen condensation intermediate to give a product external aldimine which is
then hydrolysed to release KDS (Fig. 1). Since LCS effectively acts as an amino donor to
generate PMP, the enzyme has to be regenerated by addition of excess PLP (Fig. 4). In
contrast to LCS, DCS is a much slower inactivator of SPT and this suggests it forms a
PLP:DCS external aldimine which can react via a similar decarboxylative mechanism,
possibly requiring some conformational change of the ring opened intermediate to promote
this step (Fig. 8B). To probe the formation of intermediates during SPT inactivation by both
enantiomers we utilised a SPT R378N mutant since this residue forms a salt bridge with the
carboxylate of the external aldimine with L-ser. Again, we saw clear enantiospecific
differences in the behaviour of this mutant with LCS and DCS by UV-vis spectroscopy (Fig.
7). Incubation of SPT R378N with LCS gave rise to a similar spectrum to the wild-type
enzyme but lacked a shoulder at 380nm (Fig. 7A). In contrast, we were excited to observe
transient formation of a quinonoid species at 510 nm during DCS inactivation of the R378N
mutant (Fig. 7B) and we suggest that this is due to the quinonoid formed by decarboxylation
(Fig. 8B). Of interest in a previous study Fenn et al., used a Y265F mutant of alanine
racemase to probe the different LCS and DCS inactivation mechanisms of this enzyme (37).
The Y265F mutant produced only the aromatised isoxazole PLP adduct with DCS, whereas
LCS inactivation led to formation of a range of products including PMP and acetate. They
concluded that this active site residue “steers” the pathway of inactivation. In our work,
mutation of Arg378 has revealed the presence of transient species and may be useful to
capture intermediates in future.
LCS is commonly used in biological research to inhibit de novo biosynthesis of
sphingolipids in mammalian cells but it remains debatable whether it specifically targets
SPT. LCS was shown to be a potent inhibitor of SPT activity derived from mouse brain
microsomes (50) and inhibited mouse brain SPT activity in vivo after intraperitoneal
injection (51). On the other hand cycloserine toxicity in Chinese hamster ovary cells was not
attributed to SPT inhibition since exogenous sphingosine could not rescue cell death (52).
Further research is required to examine whether LCS targets SPT alone or can inhibit other
PLP-dependent enzymes on the sphingolipid biosynthetic pathway such as sphingosine-1-
phosphate lyase. With knowledge gained from our study of the bacterial, homodimeric SPT,
it will be interesting to characterise the products of LCS and DCS inhibition of the
heterodimeric human enzyme. Whether the β-aminooxyacetaldehyde derivative is produced
by the more complex mammalian isoforms remains to be seen. The identification of two
small subunits (ssSPTa and ssSPTb) that stimulate human SPT activity >100 fold should
facilitate the analysis of cycloserine inactivation products (53).
Interestingly DCS is a much more potent inhibitor of alanine racemase compared to the
synthetic LCS (23). When the antibacterial effect of DCS and LCS was tested on a large
number of bacterial strains, most had lower tolerance towards DCS (54). In contrast, the
sphingolipid-producing bacterium Bacteroides levii was much more susceptible to LCS than
DCS which correlated to inhibition of SPT (50). Future investigations are necessary to
determine whether LCS could target sphingolipid-producing bacterial pathogens.
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Materials
Plasmids and Escherichia coli competent cells were purchased from Novagen, and all
chromatography columns were from GE Healthcare. All buffers and reagents including LCS
and DCS were from Sigma. Palmitoyl CoA was from Avanti Lipids.
Methods
Cloning and expression of S paucimobilis SPT wild-type and R378N mutant
The SPT wild-type gene and R378N mutant were cloned in pET28a expression vector
(Novagen) as previously described (20). The plasmids were transformed into E coli BL21
(DE3) competent cells and selection was carried out on LB agar containing 30 μg/ml
kanamycin. A single colony was used to inoculate an overnight culture grown at 37°C in
500 ml 2YT broth (16 g/litre Bacto-tryptone, 10 g/litre Bacto-yeast extract, 5 g/litre sodium
chloride (pH 7.5)). This culture was added to 4 litres of 2YT supplemented with kanamycin
and grown to OD600 of 0.6 before addition of 0.1 mM isopropyl 1-thio-β-D-
galactopyranoside to induce protein expression. Growth was continued for 5 hours at 30°C.
Cells were harvested (Sorvall RC5B centrifuge) by centrifugation at 3500 rpm for 20
minutes at 4°C. The enzyme was purified using IMAC on nickel resin (Invitrogen) as well
as size exclusion chromatography (Sephadex S200HR, GE Healthcare). Before UV-vis
spectroscopy and inactivation assays, the enzyme was freshly converted to the PLP-bound
form by dialysis against buffers containing 25 μM PLP.
UV-visible spectroscopy of SPT inhibition by cycloserine
All UV-visible spectra were recorded on a Cary 50 UV-visible spectrophotometer (Varian)
and analysed using Cary WinUV software (Varian). Enzyme was dialysed against 20 mM
potassium phosphate (pH 7.5) containing 150 mM NaCl and 25 μM PLP for 4 hours at 4°C.
Excess PLP was removed on a PD-10 (Sephadex G-25M) desalting column (GE
Healthcare). For UV-visible assays, the concentration of recombinant protein was 20 μM.
The spectrophotometer was blanked with 20 mM potassium phosphate (pH 7.5) containing
150 mM NaCl and spectra were collected from 800 nm to 200 nm. Quartz cuvettes from
NSG Precision Cells, Type 18-BM (Material quartz, Lightpath 10mm) had a sample volume
of 500 μl. By setting the instrument to cycle mode and collecting spectra at time intervals,
changes in the UV-visible spectrum were monitored after addition of cycloserine.
Rates of SPT inactivation by cycloserine using DTNB assay
SPT activity was measured using the DTNB assay as previously described (20). Assays
contained enzyme, substrates and DTNB with final concentrations as follows: 1 μM
enzyme, 25 mM L-serine, 250 μM palmitoyl-CoA, 0.2 mM DTNB in 20 mM HEPES buffer,
pH 8.0. SPT was incubated with LCS (0 mM, 0.63 mM, 1.25 mM, 2.5 mM and 5 mM) and
DCS (0 mM, 10 mM, 20 mM, 40 mM and 80 mM). At time intervals an aliquot of the
enzyme plus inhibitor solution was diluted into the assay buffer to record the activity. The
remaining activity was calculated as a percentage of the total activity in the absence of
inhibitor i.e. at time zero. Kitz and Wilson plots of ln % remaining activity against time were
linear (32). Graphs were plotted using WinCurveFit software, Kevin Raner, Australia.
Isolation and derivitisation of aldehyde followed by detection by LC-MS
SPT (100μM) was inactivated with 5 mM LCS for 2 hours followed by centrifugation at
13000 rpm for 10 minutes in a Vivaspin 500 concentrators (VWR) to separate the low and
high molecular weight material. The filtrate (0.1 ml) was added to a 2, 4-DNP solution (0.5
ml) prepared in acetonitrile and containing 0.5 % HCl. The solution was incubated at 37°C
for 30 minutes to allow derivitisation of the aldehyde. The hydrazone product was detected
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by LC-MS on a 6130 quadrupole mass spectrometer with a 1200 Series quaternary LC
system (Agilent Technologies). Sample volumes were typically 10 μl under automated
injection into a LC system equipped with a C18 column followed by separation in a
methanol:water:formic acid (80:19:1) mobile phase. The mass spectrometer was set up in
selected ion monitoring (SIM) mode to search for ions with masses corresponding to the β-
aminoacetaldehyde and its 2, 4-DNP hydrazone derivative (Supplementary Fig. 2).
Structural biology
Crystals of LCS-inactivated SPT were prepared by co-crystallisation. A 10mM stock
solution of LCS was prepared and added to freshly prepared holo-SPT (20 μM, in 10 mM
Tris 7.5, 150 mM NaCl and 25 μM PLP) to give a final LCS concentration of 1mM . After
overnight incubation at 4 °C, the protein was concentrated to 20 mg/ml and this solution was
used to set up crystal trials. Colourless SPT:LCS crystals grew from a 2 μl drop consisting
of 1 μl of the SPT/LCS solution and 1 μl of well solution (100 mM HEPES pH 6.5, 110 mM
MgCl2, 21.5 % PEG 3350). A single crystal was mounted in a cryo-loop and cryo-protected
in 22% PEG 3350, 120 mM MgCl2, 100 mM HEPES pH 6.5, 20% PEG400. The crystal was
frozen and data obtained that diffracted to a resolution of 1.40 Å on beamline ID14-1
(wavelength = 0.934 Å) at 100 K. Data were collected on and processed to 1.40 Å using
XDS (55). The structure was solved by molecular replacement using the 1.3 Å holo form as
the model (with co-factor and water molecules removed). Due to an oversight a new Free-R
set was devised for the structure, more rigorous would have to be use the same as the
isomorphous search model. To overcome the bias in the Free-R set, all the ligands and
waters were removed, the B-factors reset to a common value and then the structure was
refined. TLS groups were defined using the TLS server (56) and once again the B-factors
reset to a single value. The asymmetric unit contains a monomer of protein, but as with the
native contains a functional dimer. he structure was refined using REFMAC5 (57), TLS
groups were used and in the final steps of refinement anisotropic thermal factors were
refined for all atoms. Inclusion of anisotropic B-factors decreases R-free by 0.6% and was
therefore judged appropriate. PMP was modelled into the difference electron density
immediately after molecular replacement, the density was unambiguous. The choice of PMP
not PLP was made based on mass spectrometric data not the X-ray data themselves. Water
molecules were added manually and checked using COOT (58). A dictionary of the
aldehyde was made using the PRODRG server (59). The aldehyde was not included in the
final model. Its inclusion did not perturb either the R-factor or the stereochemical quality of
the model. The data collection and refinement statistics are given in Supplementary Table.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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2,4-DNP 2,4-dinitrophenylhydrazine
DCS D-cycloserine
DTNB dithionitrobenzoic acid
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LC ESI-MS liquid chromatography electrospray ionisation mass spectrometry
LCS L-cycloserine
PLP pyridoxal 5′-phosphate
PMP pyridoxamine 5′-phosphate
SPT serine palmitoyltransferase
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Fig. 1.
Catalytic mechanism of SPT.
Lowther et al. Page 14
Mol Biosyst. Author manuscript; available in PMC 2013 June 03.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Fig. 2.
(A) Structures of SPT substrates and inhibitors. (B) Mechanism of formation of the aromatic
adduct observed in each of the crystal structures shown in Table 1. (C) Proposed mechanism
of LCS inactivation of SPT by Ikushiro et al. (30).
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Fig. 3.
(A) Inactivation of SPT by LCS at inhibitor concentrations of 0, 0.625, 1.25, 2.5 and 5 mM.
(B) Inactivation of SPT by DCS at inhibitor concentrations of 0, 10, 20, 40 and 80 mM. (C)
Secondary plot of 1/kapp versus 1/[inhibitor] for LCS and DCS.
Lowther et al. Page 16
Mol Biosyst. Author manuscript; available in PMC 2013 June 03.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Fig. 4.
Inhibition of SPT activity by LCS and DCS and regeneration of activity by dialysis against
PLP buffer. SPT activity of the following samples was measured by DTNB assay: (A). 20
μM SPT (B). 20μM SPT and 5 mM LCS at 25°C after 2 hour incubation (C) Sample B after
dialysis against 20 mM potassium phosphate buffer pH 7.5 (D) Sample B after dialysis
against 20 mM potassium phosphate pH 7.5 and containing 25 μM PLP (E) 20 μM SPT and
5 mM DCS at 25°C after 2 hour incubation (F) Sample E after dialysis against 20 mM
potassium phosphate buffer pH 7.5 (G) Sample E after dialysis against 20 mM potassium
phosphate pH 7.5 and containing 25 μM PLP.
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Fig. 5.
(A) SPT and 5 mM LCS at time 0 (solid line), 30 seconds (long dash), 1 minute (dotted line)
and 30 minutes (dash dot). (B) SPT and 5 mM DCS at time 0 (solid line), 30 seconds (long
dash), 2 hours (dotted line) and 10 hours (dash dot).
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Fig. 6.
(A) Fo-Fc electron density for the PMP molecule. This was calculated from molecular
replacement model which was refined and had omitted the co-factor. The map is contoured
in green at 3σ (0.2 Å−3). Also shown are the side chains of Lys265, His159, Asp231 and
His234. Monomer A is shown in ribbon in cyan and monomer B in magenta. The additional
Fo-Fc electron density “blob” is shown in blue, contoured at 2.7 σ (0.2 Å−3). A molecule of
the β-aminooxyacetalaldehyde identified by mass spectrometry is placed in the density.
Carbons are colored yellow, nitrogen blue, oxygen red and phosphorous orange. (B) Overlay
of SPT:L-ser (2bwj) and the LCS inactivated form. The loop containing R378 adopts the
“swung out” conformation in the LCS form, in contrast to the “swung in” conformation in
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SPT:L-ser. The color scheme for the LCS inhibited form is as Fig. 6A. For the SPT:L-ser
structure, monomer A is colored light blue. Carbons are colored green, other atoms are
colored the same as in Fig. 6A. The main chain of R378 adopts a very different
conformation from the SPT:L-ser structure because the salt contact with L-ser is missing. A
well ordered molecule (red sphere) in the LCS structure is found in the same location as the
L-ser carboxylate. The side chain of L-ser points towards the unfitted blob at the active site.
This figure was prepared using PyMol (http://www.pymol.org/).
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Fig. 7.
(A) R378N and 5mM LCS at time 0 (solid line), 30 seconds (long dash), 4 minutes (dotted
line) and 30 minutes (dot dash). (B) R378N and 5 mM DCS at time 0 (solid line), mixing
time (long dash), 30 min (dot dash).
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Fig. 8.
(A) Novel ring-opening, decarboxylative mechanism for inactivation of SPT by LCS. Path
(a) denotes an enzymatic, nucleophile(Nu)-mediated mechanism with an acylated
intermediate. Path (b) is the direct hydrolytic mechanism. (B) Inactivation of SPT by DCS
highlighting a proposed quinonoid intermediate observed in the SPT R378N mutant. The
paths are the same as in (A).
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Table 1
PDB entries for PLP-dependent enzymes inactivated by CS.
Enzyme Organism Enantiomer PDB Reference
Alanine racemase Enterococcus faecalis DCS 3E6E (60)
Alanine racemase Escherichia coli DCS 2RJH (61)
Alanine racemase Streptomyces lavendulae LCS 1VFT (62)
Alanine racemase Streptomyces lavendulae DCS 1VFS (62)
Alanine racemase Bacillus stearothermophilus LCS 1NIU (23)
Alanine racemase Bacillus stearothermophilus DCS 1EPV (23)
Aminodeoxychorismate lyase Escherichia coli DCS 1I2L (63)
ArnB aminotransferase Salmonella typhimurium LCS 1MDZ (38)
Dialkylglycine decarboxylase Pseudomonas cepacia DCS & LCS 1D7S (24)
D-amino acid transferase Bacillus species DCS 2DAA (46)
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